Table 2 Outcomes according to treatment arm
From: Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD – PILOT trial
Characteristic | Empagliflozin, N = 381 | Control N = 381 | p-value2 |
|---|---|---|---|
Ejection fraction decreased by 10% | 2 (5.3%) | 10 (26%) | 0.012 |
GLS decreased by 15% | 2 (5.3%) | 12 (32%) | 0.003 |
NT-proBNP elevation | 4 (11%) | 9 (24%) | 0.13 |
cTnI elevation | 6 (16%) | 11 (29%) | 0.2 |
Ejection fraction | 56.8 (5.8) | 53.7 (6.7) | 0.029 |
Clinical heart failure | 1 (2.6%) | 6 (16%) | 0.11 |
Decreased GFR | 1 (2.6%) | 4 (11%) | 0.4 |
NYHA functional class | 0.4 | ||
I | 13 (76%) | 9 (53%) | |
II | 3 (18%) | 5 (29%) | |
III | 1 (5.9%) | 3 (18%) | |
IV | 0 (0%) | 0 (0%) | |
Death or hospitalization due to heart failure | 1 (2.6%) | 3 (7.9%) | 0.6 |